Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc.

ABSTRACT: First designed and published in 1998 as a laboratory tool to study Myc perturbation, Omomyc has come a long way in the past 22 years. This dominant negative has contributed to our understanding of Myc biology when expressed, first, in normal and cancer cells, and later in genetically-engineered mice, and has shown remarkable anti-cancer properties in a wide range of tumor types. The recently described therapeutic effect of purified Omomyc mini-protein-following the surprising discovery of its cell-penetrating capacity-constitutes a paradigm shift. Now, much more than a proof of concept, the most characterized Myc inhibitor to date is advancing in its drug development pipeline, pushing Myc inhibition into the clinic.

SUBMITTER: Masso-Valles D 

PROVIDER: S-EPMC7226798 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature